Last reviewed 2026-04-20 · How we verify

Humalog

At a glance

Approved indications

• Diabetes mellitus type 1
• Diabetes mellitus type 2

Common side effects

• Pruritus (with or without rash)
• Infusion site reactions
• Hypoglycemia
• Injection site reactions
• Lipodystrophy
• Weight gain
• Peripheral edema
• Local allergy (redness, swelling, itching at injection site)
• Infusion site erythema

Serious adverse events

• Anaphylaxis/Systemic allergy (generalized allergy, whole body rash, dyspnea, wheezing, hypotension, tachycardia, diaphoresis)
• Worsening of diabetic retinopathy
• Acute painful peripheral neuropathy
• Ophthalmologic refraction disorder

Key clinical trials

• Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
• Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (NA)
• Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
• Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
• A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes (PHASE1)
• Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog® (PHASE1)
• Oral Anti Diabetic Agents in the Hospital (PHASE4)
• Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.